Braeburn Pharmaceuticals filed plans for a $150 million initial public offering last week with the Securities & Exchange Commission, leaving out any specific pricing details. The Princeton, N.J.-based company plans to list its shares on the Nasdaq market under the symbol “BBRX”. JPMorgan, Merrill Lynch and Deustche Bank are underwriters for the offering and Apple […]
Funding Roundup
Mesoblast gains on A$29m investment deal with Mallinckrodt
Shares in stem cell company Mesoblast Ltd (ASX:MSB) rose 7% to A$1.51 yesterday after it said that it entered into an equity purchase agreement with US drugmaker Mallinckrodt Pharmaceuticals (NYSE:MNK). Mallinckrodt will buy 20.04 million, or nearly 5%, of Mesoblast’s ordinary shares for A$1.48 apiece. According to the agreement, Mallinckrodt will have 9 months to […]
Cerus raises funds for phase III trial of Intercept red blood cell system
Cerus Corporation (NSDQ:CERS) said today that it exercised $10.8 million in additional options from its contract with the Biomedical Advanced Research & Development Authority, a part of the U.S. Dept. of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response. The funds will go towards in vitro pathogen inactivation and red blood cell […]
Bayer, Versant close $225m Series A to launch stem cell company
Bayer (ETR:BAYN) and Versant Ventures said today that the 2 groups closed a $225 million Series A financing round to launch BlueRock Therapeutics, a regenerative medicine company focused on developing induced pluripotent stem cell therapies. The funds are estimated to support the company for 4 years as it advances cell therapy clinical programs for cardiovascular and degenerative diseases. “Accessing […]
Vapogenix closes $8.2m Series C for topical painkiller
Vapogenix Inc. said yesterday that it raised $8.2 million in a Series C financing round to fund the development of its locally-acting painkiller. Pamoja Capital and a group of pain physicians led the round. The Houston, Texas-based company’s technology is a topical formulation of volatile anesthetics, which are normally inhaled as general anesthesia. Vapogenix has developed […]
SRI wins $150m grant to develop HIV prevention products
SRI International said today that it landed a $150 million contract from the National Institutes of Health‘s National Institute of Allergy and Infectious Diseases and the Division of AIDS to support the development of HIV microbicides and other pre-exposure agents. According to the 7-year deal, the research institute will provide preclinical product development services for non-vaccine […]
Impel NeuroPharma closes $36m series C round for intranasal CNS treatments
Impel NeuroPharma Inc. said today that it closed a $36 million series C financing round to fund its pipeline of precision olfactory delivery (POD) intranasal devices. Life science firms venBIO, 5AM Ventures and Vivo Capital made investments in the round. Seattle-based Impel will get $21 million upfront and $15 million after it reaches development and […]
Counterfeit prescription drug tracker raises $52m
TraceLink Inc. said yesterday that it raised $51.5 million in a Series C financing round, bringing its total raised to $77 million. The round was led by Goldman Sachs Growth Equity, joining FirstMark Capital, Volition Capital and F-Prime Capital. TraceLink developed a cloud-based global network of manufacturers, distributors, pharmacies and healthcare professionals. The firm’s system enables […]
Galera adds $15m for Series B
Galera Therapeutics said today that it landed $15 million for its severe oral mucositis treatment, bringing its Series B financing total to $57 million. Sofinnova Ventures led the round, joining existing investors New Enterprise Associates, Novartis Venture Fund, Novo Ventures, Correlation Ventures, Enso Ventures and Galera Angels. The Malvern, Penn.-based company said the proceeds will be […]
Catalent to float $400m debt offering
Catalent (NYSE:CTLT) said today that it plans to fund its acquisition of soft-gel pharmaceutical capsule manufacturer Accucaps Industries Ltd with a $400 million debt offering. The Somerset, N.J.-based company said the private placement offering of euro-dominated senior unsecured notes due in 2024 will also be used to repay some of the outstanding borrowings under its senior […]
